Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Relay Therapeutics, Inc. Director's Dealing 2021

Jan 30, 2021

32320_dirs_2021-01-29_ee69c23c-c910-47ec-9cfb-216df27c0ef1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Relay Therapeutics, Inc. (RLAY)
CIK: 0001812364
Period of Report: 2021-01-28

Reporting Person: Adams Brian (General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-28 Common Stock M 5000 $4.12 Acquired 15000 Direct
2021-01-28 Common Stock S 5000 $55.05 Disposed 10000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-28 Stock Option (Right to Buy) $4.12 M 5000 Disposed 2028-03-22 Common Stock (5000) Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.